Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific Corp.

www.bostonscientific.com

Latest From Boston Scientific Corp.

Market Intel: Minimally Invasive Procedures Gaining Traction In BPH Treatment Market

Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Landmark studies of newer techniques have led the American Urological Association to update its guidelines.

Market Intelligence Cancer

Study Says FDA Waited Too Long To Ban Pelvic Mesh For POP Repairs

Roughly 18.5% of patients who received reinterventions to fix mesh implants for pelvic organ prolapse (POP) repair experienced complications they will likely endure for the rest of their lives, and they also face a 2.5% higher rate of further surgeries than non-mesh patients, says a recent 54,194-woman study detailed in Obstetrics & Gynecology. The study authors lay out a case that the US FDA should have forced removal of mesh from the market sooner.

Regulation FDA

Boston Scientific Expects Up To $40M Impact In Q1 From Coronavirus Outbreak; 10%-12% Revenue Increase For 2020

Boston Scientific said in an earnings call it expects the coronavirus outbreak may lead to a $10m to $40m loss in first-quarter sales as a result of lower procedures volumes and disrupted supply chains in China. For the fourth quarter, Boston Scientific reported $2.9bn in sales.

Sales & Earnings Companies

NANS 2020: Boston Scientific Expects Neuromodulation Business Rebound In 2020

At NANS, Boston Scientific presented results of the COMBO study, announced a partnership with IBM Research on digital health, and reported strong US growth in its deep brain stimulation business. Boston's C suite sees rebound for lagging neuromodulation business in 2020.

Neurology Clinical Trials
See All

Company Information

UsernamePublicRestriction

Register